Leonel F. Hernandez‐Aya
University of Miami(US)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses
Most-Cited Works
- → Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma(2018)1,816 cited
- → PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma(2018)1,358 cited
- → Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial(2020)462 cited
- → Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo(2020)425 cited
- → Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial(2021)373 cited
- → Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer(2019)326 cited
- → Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial(2020)271 cited
- → Targeting the Phosphatidylinositol 3-Kinase Signaling Pathway in Breast Cancer(2011)176 cited
- → Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma(2018)175 cited
- → Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing(2020)172 cited